机构:[1]The Second Clinical School of Medicine, Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangdong, 510120, China.广东省中医院
This study was supported by National Natural Science Foundation of China (No. 82274279, to Q.L.), Guangdong Provincial Bureau of Chinese medicine Fund Project (No. 20221360, to Q.L.), Municipal School (College) Joint Funding Project of Guangzhou Science and Technology Bureau (No. 202201020382, to R.Y.), Zhuhai Medical Science and Technology Research Fund Project (No. ZH24013310210002PWC, to Q.L.), Special Funding for Chinese medicine Science and Technology Research of Guangdong Provincial Hospital of Chinese Medicine (No. YN2020QN10, to Q.L.), and Municipal School (College) Joint Funding Project of Guangzhou Science and Technology Bureau (No. SL2023A03J00081, to Q.L.).
第一作者机构:[1]The Second Clinical School of Medicine, Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangdong, 510120, China.
通讯作者:
通讯机构:[1]The Second Clinical School of Medicine, Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangdong, 510120, China.[*1]The Second Clinical School of Medicine, Guangzhou University of Chinese Medicine, # 111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China.
推荐引用方式(GB/T 7714):
Yang Rongyuan,Gu Yingming,Qin Jinying,et al.Potential role of Chinese medicine nanoparticles to treat coronary artery disease[J].HELIYON.2023,9(9):doi:10.1016/j.heliyon.2023.e19766.
APA:
Yang Rongyuan,Gu Yingming,Qin Jinying,Liu Qingqing&Liu Qing.(2023).Potential role of Chinese medicine nanoparticles to treat coronary artery disease.HELIYON,9,(9)
MLA:
Yang Rongyuan,et al."Potential role of Chinese medicine nanoparticles to treat coronary artery disease".HELIYON 9..9(2023)